Investigating the impact of arginine depletion with chemotherapy in aggressive prostate cancers
Official title: Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)
Funded at University of Tx Md Anderson Can Ctr · NIH-10932183 · Data updated 2026-11-12
This study is looking at how lowering levels of an amino acid called arginine might make chemotherapy work better for men with aggressive prostate cancer that doesn't respond well to regular treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 21, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $604,748 |
| NIH project number | 5R01CA283402-02 |
| Project ID | NIH-10932183 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with aggressive variant prostate cancers who have limited treatment options.
✕Less likely to help
Patients with non-aggressive prostate cancers or those who do not have AVPC may not benefit from this research.
What this research studies
This research focuses on aggressive variant prostate cancers (AVPC), which are known to be resistant to standard treatments. The study aims to explore how depleting arginine, an amino acid, can enhance the effectiveness of platinum-taxane chemotherapy in these cancers. By analyzing patient samples and conducting trials, the researchers hope to identify new combination therapies that can improve treatment outcomes for men with AVPC. The approach includes using agents that specifically target arginine metabolism, which has shown promise in preliminary studies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with aggressive variant prostate cancers.
How similar studies have gone: Preliminary studies have shown promising results with similar approaches, indicating potential for meaningful advancements in treatment.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Aparicio, Ana — University of Tx Md Anderson Can Ctr
- Study coordinator: Aparicio, Ana
Related research
Other NIH-funded projects on the same topics.
-
Ariginine-depleting therapy plus chemotherapy for aggressive variant prostate cancers
This project tests whether removing arginine from the body enhances chemotherapy for men with a difficult-to-treat prostate cancer subtype.
-
Lowering arginine with chemotherapy for aggressive prostate cancer
Looks at whether lowering a nutrient called arginine together with platinum‑taxane chemotherapy can help men with aggressive, treatment‑resistant prostate cancer.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
A 3D ultrasound scanner to see early chemotherapy response in breast cancer
A new 3D ultrasound imaging method will be tested to see if it can quickly show whether breast cancer is responding to chemotherapy.
-
Non-invasive, microscopic biomarkers to detect CIPN in chemotherapy patients
This grant aims to develop a non-invasive imaging method to measure nerve changes in patients undergoing chemotherapy to better understand and monitor chemotherapy-induced peripheral neuropathy (CIPN).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.